Articles and Blogs

UPDATE: Shortly after this alert was published, the Supreme Court granted an administrative stay of the Fifth Circuit’s order. This means that, while the Supreme Court reviews Danco’s and GenBioPro’s emergency requests that the Fifth Circuit’s stay be vacated, mifepristone is available under the 2023 REMS, which permits dispensing of mifepristone directly to patients by... READ MORE

On June 13, 2024, the Supreme Court of the United States unanimously rejected a challenge to the U.S. Food & Drug Administration (“FDA”) approval and regulation of mifepristone (brand name “Mifeprix”), a drug used in medically induced abortions. In a 9-0 decision delivered by Justice Brett Kavanaugh, the Supreme Court held that the plaintiffs,... READ MORE